Cadrenal Therapeutics, Inc. (CVKD) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on September 24, 2025. Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, is incorporated in Delaware with principal executive offices in Ponte Vedra, Florida. The company's common stock trades on the Nasdaq Capital Market under the symbol CVKD.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (July 28, 2025), there were 2,046,854 shares of Common Stock issued and outstanding. A quorum was established with 1,284,746 shares present in person or by proxy. Stockholders voted on two proposals:
- Proposal 1: Election of Directors
- Steven Zelenkofske was elected as a Class III director to serve until the 2028 annual meeting.
- Votes For: 669,494
- Votes Withheld: 15,099
- Broker Non-Votes: 600,153
- Proposal 2: Auditor Ratification
- Stockholders ratified the appointment of WithumSmith+Brown, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 1,207,152
- Votes Against: 64,913
- Abstentions: 12,681
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (2,046,854) and the quorum threshold met (1,284,746 shares).
- Note the significant number of broker non-votes (600,153) on the director election, which did not count toward the total votes cast but indicates shares held by brokers without voting instructions.
- Confirm the tenure of the newly elected director, Steven Zelenkofske, extending to the 2028 annual meeting.
- Review the definitive proxy statement filed on July 31, 2025, for detailed background on the proposals.